Kulkarni Apurv, Kelkar Devaki A, Parikh Nidhi, Shashidhara Lingadahalli S, Koppiker Chaitanyanand B, Kulkarni Madhura
Indian Institute of Science Education and Research, Pune, India.
Prashanti Cancer Care Mission, Pune, India.
JCO Glob Oncol. 2020 Jul;6:1052-1062. doi: 10.1200/GO.20.00054.
Breast cancer is the most common cancer in women in India, with higher incidence rates of aggressive subtypes, such as triple-negative breast cancer (TNBC).
A systematic review was performed to compute pooled prevalence rates of TNBC among patients with breast cancer, and clinical features at presentation were systematically compared with non-TNBC in an Indian cohort of 20,000 patients.
Combined prevalence of TNBC among patients with breast cancer was found to be on the higher side (27%; 95% CI, 24% to 31%). We found that the estrogen receptor (ER) expression cutoff used to determine ER positivity had an influence on the pooled prevalence and ranged from 30% (ER/progesterone receptor [PR] cut ff at 1%) to 24% (ER/PR cutoff at 10%). Odds for TNBC to present in the younger age-group were significantly higher (pooled odds ratio [OR], 1.35; 95% CI, 1.08 to 1.69), with a significantly younger mean age of incidence (weighted mean difference, -2.75; 95% CI, -3.59 to -1.92). TNBC showed a significantly higher odds of presenting with high grade (pooled OR, 2.57; 95% CI, 2.12 to 3.12) and lymph node positivity (pooled OR, 1.39; 95% CI, 1.21 to 1.60) than non-TNBC.
Systematic review and meta-analysis of 34 studies revealed a high degree of heterogeneity in prevalence of TNBC within Indian patients with breast cancer, yet pooled prevalence of TNBC is high in India. High proportions of patients with TNBC present with aggressive features, such as high grade and lymph node positivity, compared with patients without TNBC. We emphasize the need for standardized methods for accurate diagnosis in countries like India.
乳腺癌是印度女性中最常见的癌症,三阴性乳腺癌(TNBC)等侵袭性亚型的发病率更高。
进行了一项系统评价,以计算乳腺癌患者中TNBC的合并患病率,并在一个20000例患者的印度队列中,将TNBC患者与非TNBC患者的临床表现进行系统比较。
发现乳腺癌患者中TNBC的合并患病率偏高(27%;95%CI,24%至31%)。我们发现,用于确定雌激素受体(ER)阳性的ER表达临界值对合并患病率有影响,范围从30%(ER/孕激素受体[PR]临界值为1%)到24%(ER/PR临界值为10%)。TNBC在较年轻年龄组出现的几率显著更高(合并优势比[OR],1.35;95%CI,1.08至1.69),发病的平均年龄显著更年轻(加权平均差,-2.75;95%CI,-3.59至-1.92)。与非TNBC相比,TNBC表现为高级别(合并OR,2.57;95%CI,2.12至3.12)和淋巴结阳性(合并OR,1.39;95%CI,1.21至1.60)的几率显著更高。
对34项研究的系统评价和荟萃分析显示,印度乳腺癌患者中TNBC的患病率存在高度异质性,但在印度TNBC的合并患病率较高。与非TNBC患者相比,高比例的TNBC患者具有侵袭性特征,如高级别和淋巴结阳性。我们强调在印度等国家需要采用标准化方法进行准确诊断。